Okamura, Shintaro https://orcid.org/0000-0002-1205-6883
Niihata, Kakuya https://orcid.org/0000-0001-9836-5750
Nishiwaki, Hiroki https://orcid.org/0000-0001-7365-7685
Tsujii, Satoru https://orcid.org/0000-0002-1834-6515
Ishii, Hitoshi https://orcid.org/0000-0002-6214-0557
Hayashino, Yasuaki https://orcid.org/0000-0002-2932-8478
Kurita, Noriaki https://orcid.org/0000-0003-4127-7500
,
Tsujii, Satoru
Kitatani, Masako
Matsunaga, Satoshi
Takano, Kiyoko
Sakuramachi, Yui
Kurosawa, Kentaro
Fujimura, Masaki
Ishii, Hitoshi
Kuwata, Hirohito
Iburi, Tadao
Kondo, Yaeko
Ueda, Rei
Fujita, Naotaka
Kurokawa, Rie
Mashitani, Tsuyoshi
Furuya, Miyuki
Nishiura, Kaori
Tanaka, Masami
Funding for this research was provided by:
Manpei Suzuki Diabetes Foundation
Japan Society for the Promotion of Science (19K10497, 16K08897, 25460641, 21790580)
Article History
Received: 20 March 2023
Accepted: 23 May 2023
First Online: 29 June 2023
Declarations
:
: HN received a research grant from the Japan Society for the Promotion of Science (JSPS). HI received honoraria for lectures and presentations from Eli Lilly Japan K.K., Merck & Co., Inc., Sanofi K.K., AstraZeneca K.K., and Novo Nordisk Japan and Sumitomo Pharma and participated in Novo Nordisk Japan’s Data Safety Monitoring Board or Advisory Committee. YH received a research grant from the JSPS, consulting fees from Ono Pharmaceutical Co., Ltd., and honoraria for lectures and presentations from Ono Pharmaceutical Co., Ltd., Boehringer Ingelheim, Merck & Co., Inc., Kowa Pharmaceuticals, Inc., Daiichi Sankyo Company, Ltd., Sumitomo Dainippon Pharma Co., Ltd., Eli Lilly Japan K.K., Teijin Pharma Limited, Novo Nordisk Pharma Ltd., and Sanofi KK. The other authors have no conflicts of interest to disclose.
: This study was conducted according to the Declaration of Helsinki and was approved by the Institutional Review Board of Tenri Hospital (study approval number: 317). Written informed consent was obtained from all study participants.